Journal article
Effect of rosiglitazone on peroxisome proliferator‐activated receptor γ gene expression in human adipose tissue is limited by antiretroviral drug–induced mitochondrial dysfunction
The Journal of Infectious Diseases, Vol.198(12), pp.1794-1803
2008
Abstract
Background. Treatment of human immunodeficiency virus (HIV)-1 with thymidine-analogue nucleoside reverse-transcriptase inhibitors (tNRTIs) causes lipoatrophy, mitochondrial toxicity, and lower adipose tissue expression of peroxisome proliferator-activated receptor γ (PPARγ [PPARG gene]) . Rosiglitazone (RSG), a PPARγ agonist, improves congenital lipoatrophy but not HIV lipoatrophy.
Methods. Serial fat biopsies were taken from HIV-infected, lipoatrophic men randomized to receive RSG or placebo for 48 weeks. Adipose tissue mitochondrial and nuclear gene expression and mitochondrial DNA content were quantified by real-time polymerase chain reaction. Nonparametric analyses were applied.
Results. Subjects receiving tNRTI-containing antiretroviral therapy had lower baseline mitochondrial RNA expression and DNA content. In subjects receiving tNRTIs, exposure to RSG did not affect PPARG expression at either week 2 or 48. At week 2, RSG increased PPARG expression only in subjects not treated with tNRTIs, whereas at week 48, increased PPARG expression was observed in subjects not treated with tNRTIs, regardless of RSG use. Similar findings were observed for the PPARG-responsive gene fatty acid-binding protein 4. Changes in PPARG expression were associated with increases in limb fat mass.
Conclusions. These data suggest that in HIV-infected, lipoatrophic men, adipose PPARG expression and function are dependent on intact mitochondrial function. These data support a direct link between mitochondrial toxicity and adipose tissue PPARG expression and help explain the poor clinical response to RSG observed in clinical trials.
Details
- Title
- Effect of rosiglitazone on peroxisome proliferator‐activated receptor γ gene expression in human adipose tissue is limited by antiretroviral drug–induced mitochondrial dysfunction
- Authors/Creators
- P.W.G. Mallon (Author/Creator)R. Sedwell (Author/Creator)G. Rogers (Author/Creator)D. Nolan (Author/Creator)P. Unemori (Author/Creator)J. Hoy (Author/Creator)K. Samaras (Author/Creator)A. Kelleher (Author/Creator)S. Emery (Author/Creator)D.A. Cooper (Author/Creator)A. Carr (Author/Creator)
- Publication Details
- The Journal of Infectious Diseases, Vol.198(12), pp.1794-1803
- Publisher
- Oxford University Press
- Identifiers
- 991005540760107891
- Murdoch Affiliation
- Centre for Clinical Immunology and Biomedical Statistics
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
61 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.66 HIV
- 1.66.1372 HIV Comorbidities
- Web Of Science research areas
- Immunology
- Infectious Diseases
- Microbiology
- ESI research areas
- Immunology